Fixed-dose combination of lumacaftor / ivacaftor (Orkambi) for the treatment of cystic fibrosis in children

Introduction

The fixed-dose combination of lumacaftor / ivacaftor (trade name: Orkambi) has been approved in Germany since February 2018 for the treatment of cystic fibrosis in children between the ages of 6 and 11. As of January 2019, it can now also be given to children between the ages of 2 and 5. This medication is an option if there's a certain mutation (F508del) in a gene known as the CFTR (cystic fibrosis transmembrane conductance regulator) gene.

Cystic fibrosis is a genetic metabolic disease. It is caused by a defect in a gene called the CFTR (cystic fibrosis transmembrane conductance regulator) gene. This regulator influences the balance of salt and water in the mucus-producing gland cells, for example in the pancreas, bronchi and small intestine. The defect makes the mucus very thick and sticky. In the lungs, this thick mucus can’t be coughed up, which makes it hard to breathe and may cause a chronic cough. Bacteria can also collect in the mucus, repeatedly causing respiratory infections. Thick and sticky digestive juices damage the and reduce the body’s absorption of important nutrients in the bowel, increasing the risk of malnutrition and being underweight. The symptoms of cystic fibrosis already appear in children.

There is no cure for cystic fibrosis. The fixed-dose combination of lumacaftor / ivacaftor aims to improve the function of the CFTR, so that the mucus becomes less thick and sticky, and the symptoms improve.

Application

Lumacaftor / ivacaftor is available as tablets and granules, each at two doses:

  • Granules with 100 mg lumacaftor / 125 mg ivacaftor or with 150 mg lumacaftor / 188 mg ivacaftor
  • Tablets with 100 mg lumacaftor / 125 mg ivacaftor or with 200 mg lumacaftor / 125 mg ivacaftor

Children between 2 and 5 years of age

Children between 2 and 5 years of age take lumacaftor / ivacaftor in the form of granules every 12 hours before or after eating food containing fat. The fat helps the body to absorb the active ingredients better. The granules are mixed into a small amount of food, such as mashed fruit, fruit yogurt or milk. The food must be kept at room temperature or lower in order to not destroy the active ingredient.

The recommended dose will depend on the child's body weight. For children who weigh less than 14 kilograms (about 30 pounds), a single dose is 1 sachet of granules with 100 mg lumacaftor / 125 mg ivacaftor. For children who weigh 14 kilograms or more, a single dose is 1 sachet of granules containing 150 mg lumacaftor / 188 mg ivacaftor.

Children between 6 and 11 years of age

Children between 6 and 11 years of age take lumacaftor / ivacaftor as a tablet every 12 hours before or after eating food containing fat. The recommended single dose is 2 tablets with 100 mg lumacaftor / 125 mg ivacaftor. Tablets are swallowed whole (not chewed).

Other treatments

Children who have cystic fibrosis and the F508del mutation are given the best possible supportive (adjuvant) care. Supportive care should be tailored to the patient’s individual needs. It aims to relieve symptoms such as breathing difficulties as well as improve quality of life. It may include for lung infections, mucus-thinning medications, physiotherapy and changes to their diet.

Assessment

Children between 2 and 5 years of age

In 2019, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether the fixed-dose combination lumacaftor / ivacaftor has any advantages or disadvantages compared to best supportive care in children between 2 and 5 years of age who have cystic fibrosis and the F508del mutation.

But the manufacturer didn’t provide any suitable data with which to do the assessment.

Children between 6 and 11 years of age

In 2018, IQWiG looked into whether the fixed-dose combination lumacaftor / ivacaftor has any advantages or disadvantages compared to best supportive care in children between 6 and 11 years of age who have cystic fibrosis and the F508del mutation.

To answer this question, the manufacturer provided one study involving 204 children in that age range. 103 children were treated with the fixed-dose combination lumacaftor / ivacaftor, and 101 children were given a placebo (fake medication). All of the children also received symptom-reducing treatment. The treatment lasted 24 weeks. The results showed that the additional use of lumacaftor / ivacaftor had no benefits or drawbacks.

No difference

  • Life expectancy: None of the children died during the study.
  • Treatment stopped due to side effects: In each group, about 2 to 3 out of 100 children stopped their treatment due to side effects.
  • There were also no differences between the two groups in terms of:
    • Lung diseases getting worse
    • Difficulty breathing
    • Gastrointestinal (stomach and bowel) problems
    • Health-related quality of life
    • Serious side effects

More information

This information summarizes the main results of reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of these reviews and the hearings received, the G-BA passed a resolution on the added benefit of lumacaftor / ivacaftor (Orkambi) for children between between 6 and 11 years of age as well as children between 2 and 5 years of age.

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Lumacaftor/ivacaftor (cystic fibrosis) – Benefit assessment according to §35a Social Code Book V . Dossier assessment; Commission A18-08. April 27, 2018. (IQWiG Reports; Volume 620).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Lumacaftor/ivacaftor (cystic fibrosis) – Addendum to Commission A18-08. Commission A18-39. July 10, 2018. (IQWiG Reports; Volume 643).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Lumacaftor/ivacaftor (cystic fibrosis in children aged 2 to 5 years) – Benefit assessment according to §35a Social Code Book V . Dossier assessment; Commission A19-13. May 13, 2019. (IQWiG Reports; Volume 768).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Updated on June 6, 2019
Next planned update: 2022

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.